AI Summary
This article discusses the use of immune checkpoint inhibitors (ICIs) in the treatment of endometrial cancer (EC), which was previously a neglected disease with limited treatment options. The introduction of ICIs, especially for ECs with microsatellite instability, has shown promise in changing the treatment landscape for this type of cancer. The Cancer Genome Atlas (TCGA) molecular classification has further supported the potential of immunotherapy as a game-changing strategy for EC treatment.
Endometrial cancer (EC) has long been a ‘Cinderella disease’, receiving little attention and with limited systemic treatment options. The advent of immune checkpoint inhibitors (ICIs) marked a new era in the treatment landscape of EC. Following the results of The Cancer Genome Atlas (TCGA) molecular classification, which showed that microsatellite instability is involved in the pathogenesis of approximately 30% of all ECs (40% in endometrioid tumours), it became clear that immunotherapy could be a game-changing strategy.